Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently launched in China, Bayer Healthcare China aims to provide Chinese multiple sclerosis patients with a comprehensive range of services from diagnosis to therapy. Gadovist 1.0, a contrast agent for use in magnetic resonance imaging (MRI), has been approved in China for the diagnosis of diseases affecting the central nervous system, including MS, and for blood-vessel imaging.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.